2-氯-4-氟苯甲酸甲酯 | 85953-29-3

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-氟苯甲酸甲酯
• 中文别名: 2-氯-4-氟苯羧酸甲酯
• 英文名称: methyl 2-chloro-4-fluorobenzoate
• 英文别名: 2-chloro-4-fluorobenzoic acid methyl ester
• CAS: 85953-29-3
• 化学式: C₈H₆ClFO₂
• mdl: MFCD00173937
• 分子量: 188.586
• InChiKey: YZDLPZNWBRBZMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  110 °C
• 密度：
  1.314±0.06 g/cm3(Predicted)
• 闪点：
  103-105°C/15mm
• 稳定性/保质期：
  按规定使用和存储的该物质不会分解，并能避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 危险品运输编号：
  1993
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  存放于密闭、阴凉、干燥处

SDS

Name:	Methyl 2-chloro-4-fluorobenzoate 97% Material Safety Data Sheet
Synonym:
CAS:	85953-29-3

Section 1 - Chemical Product MSDS Name:Methyl 2-chloro-4-fluorobenzoate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
85953-29-3	Methyl 2-chloro-4-fluorobenzoate	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 85953-29-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 103 - 105 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6ClFO2
Molecular Weight: 189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 85953-29-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 2-chloro-4-fluorobenzoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 85953-29-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 85953-29-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 85953-29-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-氯-4-氟苯甲酸	2-choro-4-fluorobenzoic acid	2252-51-9	C7H4ClFO2	174.559
  2-氯-4-氟苯甲酰氯	2-chloro-4-fluorobenzoyl chloride	21900-54-9	C7H3Cl2FO	193.005
  2-氯-4-硝基苯甲酸甲酯	methyl 2-chloro-4-nitrobenzoate	13324-11-3	C8H6ClNO4	215.593

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  2-氯-4-氟苯甲醇	(2-chloro-4-fluorophenyl)methanol	208186-84-9	C7H6ClFO	160.575
  ——	methyl 2-chloro-4-(methylthio)benzoate	111986-05-1	C9H9ClO2S	216.688
  ——	2-chloro-4-dimethylamino-benzoic acid methyl ester	773874-76-3	C10H12ClNO2	213.664
  2-氯-4-氟-5-硝基苯甲酸甲酯	methyl 2-chloro-4-fluoro-5-nitrobenzoate	85953-30-6	C8H5ClFNO4	233.583
  ——	2-(2-chloro-4-fluorophenyl)propan-2-ol	51788-82-0	C9H10ClFO	188.629

反应信息

• 作为反应物：
  描述：

  2-氯-4-氟苯甲酸甲酯 在 N-甲基吡咯烷酮 、 盐酸 、 氯化亚砜 、 potassium carbonate 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 生成 VNA-932
  参考文献：
  名称：

  LIT-001，第一个在自闭症小鼠模型中改善社交互动的非肽类催产素受体激动剂

  摘要：

  催产素（OT）及其受体（OT-R）与自闭症谱系障碍（ASD）的病因有关，并且OT-R是治疗干预的潜在目标。当前已经报道了极少的非肽催产素激动剂。它们的分子和体内药理学仍有待阐明，并且没有显示它们在改善与ASD相关的动物模型中的社会互动方面有效。为了合理设计中枢活性非肽全激动剂的设计，我们以系统的方式研究了V 1a和V 2加压素受体亚型（V 1a -R和V 2）的代表性配体的亲和力和功效的结构决定因素。-R）和催产素受体。我们的研究结果证实了血管加压素/催产素受体配体周围的结构亲和力和结构功效关系的微妙之处，但是导致了在外围腹膜内注射后在ASD小鼠模型中首个活性的非肽OT受体激动剂。

  DOI：

  10.1021/acs.jmedchem.8b00697
• 作为产物：
  描述：

  2-氯-4-硝基苯甲酸甲酯 在 四丁基氟化铵 作用下， 以 二甲基亚砜 为溶剂， 反应 0.17h， 以95%的产率得到2-氯-4-氟苯甲酸甲酯
  参考文献：
  名称：

  Microwave-accelerated fluorodenitrations and nitrodehalogenations: expeditious routes to labeled PET ligands and fluoropharmaceuticals

  摘要：

  Methods for the expeditious fluorination of arenes have been investigated, using readily available fluoride sources. An optimized procedure for microwave-accelerated fluorodenitration has been developed, giving good to excellent yields in less than 10 min, rendering it practical for use in the preparation of F-18 labeled ligands for PET imaging. Application of the method in the synthesis of CNS agents is demonstrated, and a practical method for the preparation of Substrates is also presented. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.02.042

文献信息

• A new air-stable Si,S-chelating ligand for Ir-catalyzed directed <i>ortho</i> C–H borylation
  作者：Jiao Jiao、Wenzheng Nie、Peidong Song、Pengfei Li

  DOI：10.1039/d0ob02335c

  日期：——

  reaction with a broad substrate scope. This study provides the first example of using a sulfur-containing ligand in the catalytic C–H borylation process. It provides a rapid, efficient, and economical method for the preparation of organoboron compounds.

  已开发出一种新型的空气稳定的Si，S螯合配体，并用于具有广泛底物范围的铱催化的邻位C-H硼酸酯化反应中。这项研究提供了在催化C–H硼化过程中使用含硫配体的第一个例子。它提供了一种快速，有效和经济的有机硼化合物的制备方法。
• A simple reduction of methyl aromatic esters to alcohols using sodium borohydride–methanol system
  作者：Núbia Boechat、Jorge Carlos Santos da Costa、Jorge de Souza Mendonça、Pedro Santos Mello de Oliveira、Marcus Vinı́cius Nora De Souza

  DOI：10.1016/j.tetlet.2004.06.034

  日期：2004.7

  Several aromatic esters were reduced to the corresponding alcohol by using sodium borohydride–methanol system. The reduction was completed within 2.0–4.0 h after refluxing in THF. The alcohol products were isolated after aqueous workup in good yields (88–97%).

  使用硼氢化钠-甲醇系统将几种芳香族酯还原为相应的醇。在四氢呋喃中回流后，还原过程在2.0-4.0小时内完成。水处理后分离出酒精产物，收率良好（88–97％）。
• 一种作为蛋白质激酶抑制剂的化合物及其用途
  申请人：成都海博为药业有限公司

  公开号：CN112608318B

  公开（公告）日：2023-09-08

  本发明公开了一种作为蛋白质激酶抑制剂的化合物及其用途，该类化合物对蛋白质激酶活性具有明显的抑制作用，可作为BTK抑制剂，用以制备治疗由BTK介导的疾病如恶性肿瘤、自身免疫性疾病等药物中的用途，具有广阔的应用前景。
• 二氢嘧啶类化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN109111451B

  公开（公告）日：2020-08-11

  本发明涉及一种二氢嘧啶类化合物及其作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。具体地说，本发明涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。
• Thymidine analogs for imaging
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1916003A1

  公开（公告）日：2008-04-30

  The present invention relates to nucleoside analogues and more particularly to labelled nucleoside analogues of formula (I). It has been found new thymidine analogues can be stably labelled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and I or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更特别地涉及式(I)的标记核苷类似物。已发现新的胸苷类似物可以稳定地标记具有可检测标记基团。此外，本发明涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或治疗增殖性疾病。此外，本发明涉及制备和使用正电子发射化合物进行正电子发射断层扫描（PET）。还公开了一种试剂盒。